New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
November 19, 2009
06:27 EDTMNTA
theflyonthewall.com: Momenta Pharma upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Momenta Pharmaceuticals as it finds the stock attractive ahead of FDA's decision on M-enoxaparin. The firm has a $15 price target on the stock. :theflyonthewall.com



News For MNTA From The Last 14 Days
Check below for free stories on MNTA the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2012
09:54 EDTMNTA
theflyonthewall.com: Momenta Pharma gaps down after results, support is at $14.50, $14.25

Subscribe for More Information :theflyonthewall.com
09:48 EDTMNTA
theflyonthewall.com: Gappers report: Bearish gaps

Subscribe for More Information :theflyonthewall.com
08:34 EDTMNTA
theflyonthewall.com: Momenta Pharma reports Q4 EPS (2c) vs. consensus (27c)
Reports revenue $29.5M vs. consensus $38.59M. :theflyonthewall.com

February 7, 2012
13:45 EDTMNTA
theflyonthewall.com: Judge rules for FDA, against Sanofi, in generic Lovenox appeal, Bloomberg says

Subscribe for More Information :theflyonthewall.com

January 30, 2012
11:17 EDTMNTA
theflyonthewall.com: Momenta Pharma to be added to S&P 600; HealthSpring deleted as of 1/31 close

Subscribe for More Information :theflyonthewall.com